Union Bancaire Privee UBP SA Invests $282,000 in BioNTech SE (NASDAQ:BNTX)

Union Bancaire Privee UBP SA acquired a new stake in BioNTech SE (NASDAQ:BNTX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,500 shares of the company’s stock, valued at approximately $282,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of BNTX. Planning Capital Management Corp increased its holdings in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after acquiring an additional 450 shares during the last quarter. Blue Trust Inc. increased its stake in BioNTech by 491.1% during the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after purchasing an additional 388 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after buying an additional 111 shares during the last quarter. Clear Harbor Asset Management LLC acquired a new position in shares of BioNTech in the 3rd quarter valued at about $210,000. Finally, Probity Advisors Inc. acquired a new stake in BioNTech during the third quarter worth about $216,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Trading Up 3.8 %

Shares of BioNTech stock opened at $124.30 on Wednesday. The business has a fifty day simple moving average of $116.50 and a 200-day simple moving average of $106.57. The firm has a market cap of $29.80 billion, a price-to-earnings ratio of -59.19 and a beta of 0.18. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. During the same quarter last year, the firm posted $0.73 EPS. The business’s revenue for the quarter was up 38.9% on a year-over-year basis. On average, equities analysts forecast that BioNTech SE will post -3.77 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BNTX has been the subject of a number of research reports. JPMorgan Chase & Co. decreased their target price on BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a research note on Tuesday, November 26th. HSBC raised their target price on BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, October 7th. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and upped their price target for the stock from $90.00 to $137.00 in a research report on Friday, November 8th. Canaccord Genuity Group lifted their price objective on shares of BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a research report on Wednesday, November 27th. Finally, Truist Financial started coverage on shares of BioNTech in a research report on Friday, January 10th. They issued a “buy” rating and a $172.00 target price for the company. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $142.72.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.